IC
Ikarian Capital Portfolio holdings
AUM
$302M
1-Year Return
65.21%
This Quarter Return
+3.95%
1 Year Return
+65.21%
3 Year Return
+441.33%
5 Year Return
+548.26%
10 Year Return
–
AUM
$672M
AUM Growth
+$124M
(+23%)
Cap. Flow
+$84.6M
Cap. Flow
% of AUM
12.6%
Top 10 Holdings %
Top 10 Hldgs %
24.63%
Holding
266
New
64
Increased
38
Reduced
42
Closed
20
Top Buys
| 1 |
Eli Lilly
LLY
|
$23.4M |
| 2 |
MacroGenics
MGNX
|
$15.9M |
| 3 |
Galapagos
GLPG
|
$15.5M |
| 4 |
X4 Pharmaceuticals
XFOR
|
$15.4M |
| 5 |
Relmada Therapeutics
RLMD
|
$10.2M |
Top Sells
| 1 |
MORF
Morphic Holding, Inc. Common Stock
MORF
|
$29.5M |
| 2 |
KalVista Pharmaceuticals
KALV
|
$19.7M |
| 3 |
Prothena Corp
PRTA
|
$18.8M |
| 4 |
Bristol-Myers Squibb
BMY
|
$17.9M |
| 5 |
Celldex Therapeutics
CLDX
|
$15.8M |
Sector Composition
| 1 | Healthcare | 98.54% |
| 2 | Consumer Staples | 0.23% |
| 3 | Financials | 0.12% |
| 4 | Industrials | 0.02% |
